Healthcare
Immunicum announced a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate ilixadencel in combination with Avelumab in multi-indication phase Ib/II study ILIAD.
MDxHealth SA announced that positive data and observations from multiple studies and patient registries demonstrating the value of SelectMDx and ConfirmMDx for Prostate Cancer diagnosis, will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place in San Francisco, California, February 14-16, 2019.
“This is Medidata’s first office in Boston, and the company is excited for the opportunity over the next several years to tap into the amazing life sciences and technology skills that Boston can offer,” said Medidata’s chief people officer.
MDxHealth SA announces that it has signed an exclusive distribution agreement with LifeLabs to make SelectMDx®, the Company’s non-invasive liquid biopsy prostate cancer test, available in Canada.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
MDxHealth SA, announced that it received on February 7, 2019 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Hitachi, Ltd., Jichi Medical University, International University of Health and Welfare and Chuo University have developed fundamental technology to support the early differential diagnosis of concurrent autism spectrum disorder in patients with attention-deficit hyperactivity disorder.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Last week HHS floated a plan that would allow companies to pass rebates of 26 to 30 percent of a drug’s list price directly to patients in order to be reflected in what consumers pay at the pharmacy counter.
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
PRESS RELEASES